Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib DDI and QTc study
NCT04887194Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitravatinib in solid tumor (advanced stage) (3 cohorts), sponsored by Mirati Therapeutics. Primary endpoints: PK parameters of probe drugs; AUC from time zero to the last data point (AUC-last), PK parameters of probe drugs; AUC from time zero to infinity (AUC∞) and 2 more. Started Apr 2021; status: completed.
02
Drugs
sitravatinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04887194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887194.